微创肺表面活性物质治疗早产儿两年结局:OPTIMIST-A随机临床试验随访
该研究为33个三级新生儿重症监护病房参与的多国随机临床试验随访,纳入486例胎龄25至28周、接受持续气道正压通气的早产儿,比较经细导管微创肺表面活性物质治疗(MIST)与假治疗对2岁矫正年龄死亡或神经发育障碍的影响。结果显示MIST未降低死亡或神经发育障碍发生率,但呼吸相关住院和父母报告的喘息或呼吸困难发生率较低。
要点
- MIST组死亡或神经发育障碍36.3%,对照组36.1%,风险差0%(95%CI -7.6%至7.7%)。
- MIST组呼吸疾病住院25.1%,对照组38.2%(RR 0.66,95%CI 0.54-0.81)。
- MIST组父母报告喘息或呼吸困难40.6%,对照组53.6%(RR 0.76,95%CI 0.63-0.90)。
核心结论
- 在需要持续气道正压通气的呼吸窘迫综合征早产儿中,与假治疗相比,MIST未降低2岁矫正年龄时死亡或神经发育障碍的发生率。
- 接受MIST的婴儿在出生后前2年呼吸不良结局发生率较低。
研究设计与样本
- 随机临床试验随访研究,对临床医生和结局评估者设盲,在11个国家的33个三级新生儿重症监护病房开展。
- 试验纳入486例胎龄25至28周、接受持续气道正压通气的早产儿,MIST组242例,对照组244例。
- 2岁矫正年龄随访数据收集于2022年12月9日完成。
主要发现
- 共453例婴儿获得随访数据(中位胎龄27.3周;女性228例[50.3%]),434例婴儿有主要次要结局数据。
- MIST组78例(36.3%)发生死亡或神经发育障碍,对照组79例(36.1%),风险差0%(95%CI -7.6%至7.7%),相对危险度(RR)1.0(95%CI 0.81-1.24)。
- 该复合结局的各组分在两组间无显著差异。
- MIST组49例(25.1%)因呼吸疾病住院,对照组78例(38.2%),RR 0.66(95%CI 0.54-0.81)。
- MIST组73例(40.6%)父母报告喘息或呼吸困难,对照组104例(53.6%),RR 0.76(95%CI 0.63-0.90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The long-term effects of surfactant administration via a thin catheter (minimally invasive surfactant therapy [MIST]) in preterm infants with respiratory distress syndrome remain to be definitively clarified. OBJECTIVE: To examine the effect of MIST on death or neurodevelopmental disability (NDD) at 2 years' corrected age. DESIGN, SETTING, AND PARTICIPANTS: Follow-up study of a randomized clinical trial with blinding of clinicians and outcome assessors conducted in 33 tertiary-level neonatal intensive care units in 11 countries. The trial included 486 infants with a gestational age of 25 to 28 weeks supported with continuous positive airway pressure (CPAP). Collection of follow-up data at 2 years' corrected age was completed on December 9, 2022. INTERVENTIONS: Infants assigned to MIST (n = 242) received exogenous surfactant (200 mg/kg poractant alfa) via a thin catheter; those assigned to the control group (n = 244) received sham treatment. MAIN OUTCOMES AND MEASURES: The key secondary outcome of death or moderate to severe NDD was assessed at 2 years' corrected age. Other secondary outcomes included components of this composite outcome, as well as hospitalizations for respiratory illness and parent-reported wheezing or breathing difficulty in the first 2 years. RESULTS: Among the 486 infants randomized, 453 had follow-up data available (median gestation, 27.3 weeks; 228 females [50.3%]); data on the key secondary outcome were available in 434 infants. Death or NDD occurred in 78 infants (36.3%) in the MIST group and 79 (36.1%) in the control group (risk difference, 0% [95% CI, -7.6% to 7.7%]; relative risk [RR], 1.0 [95% CI, 0.81-1.24]); components of this outcome did not differ significantly between groups. Secondary respiratory outcomes favored the MIST group. Hospitalization with respiratory illness occurred in 49 infants (25.1%) in the MIST group vs 78 (38.2%) in the control group (RR, 0.66 [95% CI, 0.54-0.81]) and parent-reported wheezing or breathing difficulty in 73 (40.6%) vs 104 (53.6%), respectively (RR, 0.76 [95% CI, 0.63-0.90]). CONCLUSIONS AND RELEVANCE: In this follow-up study of a randomized clinical trial of preterm infants with respiratory distress syndrome supported with CPAP, MIST compared with sham treatment did not reduce the incidence of death or NDD by 2 years of age. However, infants who received MIST had lower rates of adverse respiratory outcomes during their first 2 years of life. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000916943.
引用
- Dargaville PA, Kamlin COF, Orsini F, et al. Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants: Follow-Up of the OPTIMIST-A Randomized Clinical Trial. JAMA. 2023. PMID: 37695601. doi:10.1001/jama.2023.15694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。